7742 related articles for article (PubMed ID: 1923993)
1. [Plasminogen activator inhibitors from neoplastic tissues].
Mirowski M; Wierzbicki R
Postepy Hig Med Dosw; 1991; 45(1-2):119-27. PubMed ID: 1923993
[TBL] [Abstract][Full Text] [Related]
2. Immunoaffinity purification of HTC rat hepatoma cell plasminogen activator-inhibitor-1.
Zeheb R; Rafferty UM; Rodriguez MA; Andreasen P; Gelehrter TD
Thromb Haemost; 1987 Dec; 58(4):1017-23. PubMed ID: 3127913
[TBL] [Abstract][Full Text] [Related]
3. The role of vascular endothelial cells in the regulation of fibrinolysis.
Grulich-Henn J; Müller-Berghaus G
Z Kardiol; 1989; 78 Suppl 6():25-9. PubMed ID: 2694664
[TBL] [Abstract][Full Text] [Related]
4. Effects of tiaprofenic acid on plasminogen activators and inhibitors in human OA and RA synovium.
Pelletier JP; McCollum R; Cloutier JM; Martel-Pelletier J
Br J Rheumatol; 1992; 31 Suppl 1():19-26. PubMed ID: 1555050
[TBL] [Abstract][Full Text] [Related]
5. Sesamol regulates plasminogen activator gene expression in cultured endothelial cells: a potential effect on the fibrinolytic system.
Chen PR; Lee CC; Chang H; Tsai CE
J Nutr Biochem; 2005 Jan; 16(1):59-64. PubMed ID: 15629242
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitors type 1 and type 2 and plasminogen activators in amniotic fluid during pregnancy.
Estellés A; Gilabert J; Andrés C; España F; Aznar J
Thromb Haemost; 1990 Oct; 64(2):281-5. PubMed ID: 2125378
[TBL] [Abstract][Full Text] [Related]
7. Detection of both type 1 and type 2 plasminogen activator inhibitors in human cells.
Schleef RR; Wagner NV; Loskutoff DJ
J Cell Physiol; 1988 Feb; 134(2):269-74. PubMed ID: 3257967
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
Heidtmann HH; Hofmann M; Jacob E; Erbil C; Havemann K; Schwartz-Albiez R
Cancer Res; 1989 Dec; 49(24 Pt 1):6960-5. PubMed ID: 2555056
[TBL] [Abstract][Full Text] [Related]
9. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
Bachmann F
Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901
[TBL] [Abstract][Full Text] [Related]
10. Expression and release of plasminogen activators, their inhibitors and receptor by human tumor cell lines.
Buø L; Bjørnland K; Karlsrud TS; Kvale D; Kjønniksen I; Fodstad O; Brandtzaeg P; Johansen HT; Aasen AO
Anticancer Res; 1994; 14(6B):2445-51. PubMed ID: 7872665
[TBL] [Abstract][Full Text] [Related]
11. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
12. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
[TBL] [Abstract][Full Text] [Related]
13. [Inhibitors of fibrinolysis with special reference to anti-t-PA (inhibitor of the tissue plasminogen activator)].
Félez J; Rueda F
Sangre (Barc); 1985; 30(4-C):779-86. PubMed ID: 3937250
[No Abstract] [Full Text] [Related]
14. Plasminogen activator inhibitor type 1: biochemistry and evidence for modulation of fibrinolysis in vivo.
Krishnamurti C; Alving BM
Semin Thromb Hemost; 1992 Jan; 18(1):67-80. PubMed ID: 1374195
[No Abstract] [Full Text] [Related]
15. Modulation of mRNA levels for urinary- and tissue-type plasminogen activator and plasminogen activator inhibitors 1 and 2 in human fibroblasts by interleukin 1.
Michel JB; Quertermous T
J Immunol; 1989 Aug; 143(3):890-5. PubMed ID: 2501387
[TBL] [Abstract][Full Text] [Related]
16. Human renal microvascular endothelial cells as a potential target in the development of the hemolytic uremic syndrome as related to fibrinolysis factor expression, in vitro.
Louise CB; Obrig TG
Microvasc Res; 1994 May; 47(3):377-87. PubMed ID: 8084301
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.
de Vries TJ; Quax PH; Denijn M; Verrijp KN; Verheijen JH; Verspaget HW; Weidle UH; Ruiter DJ; van Muijen GN
Am J Pathol; 1994 Jan; 144(1):70-81. PubMed ID: 8291613
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional regulation of tissue- and urokinase-type plasminogen activator genes by thrombin in human fetal lung fibroblasts.
Hayakawa Y; Tazawa S; Ishikawa T; Niiya K; Sakuragawa N
Thromb Haemost; 1995 Aug; 74(2):704-10. PubMed ID: 8585010
[TBL] [Abstract][Full Text] [Related]
19. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
[TBL] [Abstract][Full Text] [Related]
20. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors.
Landau BJ; Kwaan HC; Verrusio EN; Brem SS
Cancer Res; 1994 Feb; 54(4):1105-8. PubMed ID: 8313368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]